Abortion pioneer died at 93 in hospital after being diagnosed with dementia
Dr Horace Hale Harvey III, who was born in New Orleans in December 1931, opened one of the first independent abortion clinics in the US in Manhattan in July 1970 after New York State had reformed its laws.
Advertisement
The clinic, called Women's Services, provided safe and affordable abortions.
In an obituary, the New York Times reported that Dr Harvey had become an abortion provider to 'combat what he felt was an epidemic of unsafe abortions at a time when unmarried women were denied access to contraceptives, and when comprehensive sex education was discouraged'.
Dr Harvey, who had a son and a daughter, later moved to the Isle of Wight and worked for public health services there but in 2014 moved to Dorset after his house burned down.
The obituary states that Dr Harvey had chosen the Isle of Wight because 'according to his research, it had the highest average temperature and received more hours of sunlight than anywhere else in England'.
Advertisement
In a statement read to the Bournemouth inquest, his daughter Kate said that her father was 'very determined' to keep healthy by walking a mile and doing 20 squats each day and said he 'enjoyed laughter and making up jokes' as well as activities such as dance, table tennis and snooker.
Dr Harvey later worked on the Isle of Wight (Andrew Matthews/PA)
She added that he was a scholar who was 'committed to Aristotelian ethics and scientific learning'.
The inquest heard that in late 2024, Dr Harvey was diagnosed with Alzheimer's and PTSD after the house fire 10 years earlier.
On January 22 2025, he was taken to Dorset County Hospital having suffered a rib fracture in a fall at home.
Advertisement
After physiotherapists expressed concerns at his ability to understand care instructions, he was assessed by psychiatrists and was detained under the mental health act.
Coroner Richard Middleton said that Dr Harvey was increasingly experiencing delirium and paranoia.
He said that Dr Harvey was found dead in his hospital bed in the early hours of February 14 and a post-mortem examination found he died of natural causes from ischaemic heart disease and coronary artery disease.
The coroner, recording a conclusion of death by natural causes, explained that the inquest had to be held by law because Dr Harvey was formally detained by the state at the time of his death.
Advertisement
Mr Middleton added: 'I express my deepest condolences to all of Dr Harvey's family and friends for their loss.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Novo Nordisk expands lawsuits against weight-loss drug compounders
Aug 5 (Reuters) - Danish drugmaker Novo Nordisk ( opens new tab said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. The new lawsuits target pharmacies and telehealth companies producing compounded versions of semaglutide "under the fake guise of personalization", Novo said, without naming the companies. Shares of major telehealth firm Hims & Hers (HIMS.N), opens new tab extended losses to fall nearly 13% in afternoon trade. It had earlier reported weaker-than-expected quarterly revenue. A Reuters search of legal filings found some cases filed by Novo in California dated Aug. 4 but none regarding San Francisco-based Hims. Hims was not immediately available for comment. Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand. These companies were briefly allowed to produce hundreds of thousands of compounded doses of Novo's obesity and diabetes drugs when the Food and Drug Administration said they were in short supply. When the agency later banned the sale of these copies, Hims and Hers shifted to creating versions of semaglutide in personalized doses not accessible through the branded manufacturers. Novo's lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded "semaglutide" under the guise of personalized medicine. In reality, these are knockoffs that have not been approved as safe and effective and are often made with illicit foreign active pharmaceutical ingredients (API), Novo said. It did not immediately respond to a Reuters query on which companies were being named in the lawsuit.
The Independent
2 hours ago
- The Independent
The struggle to access weight-loss jabs from NHS
Thousands of obese patients in England are unable to access the weight loss jab Mounjaro due to a 'postcode lottery' in NHS provision. Data obtained by Sky News reveals only 8 of 42 NHS Integrated Care Boards (ICBs) in England are currently able to provide the treatment, despite its intended availability from 23 June. Doctors warn patients are being 'set up for failure', with claims that NHS England has only funded treatment for a fraction of the 97,500 patients NICE calculated should be treated in the first year. NHS England stated it has 'fully supported the rollout', issuing guidance and providing funding to ICBs in March to cover treatment costs and support services. Concerns also exist regarding post-treatment support, with NICE stressing the need for structured follow-up for NHS patients to prevent weight regain, a service not available to the 1.5 million private users.
Daily Mail
4 hours ago
- Daily Mail
GPs warned using AI to record patient notes can lead to dangerous inaccuracies
GPs have been warned to look out for 'inaccurate or fabricated' information when using AI to write their medical notes. Family doctors are increasingly using tools that listen to their consultations with patients and automatically add summaries to their records. But the Royal College of GPs has warned AI can misinterpret the nuance of conversations, with potential dangerous consequences. The Medicines and Healthcare products Regulatory Agency (MHRA) also says there is a 'risk of hallucination which users should be aware of, and manufacturers should actively seek to minimise and mitigate the potential harms of their occurrence'. The safety watchdog is now urging GPs to report issues with AI scribes through its Yellow Card Scheme, which is typically used to report adverse reactions to medicines. This should include 'suspected inaccuracies', trade publication GP Online reports. The British Medical Association's GP Committee said earlier this year that 'the adoption of passive scribes in general practice has gathered significant pace', with practices using standalone systems or tools rolled out with other common software. Dr Phil Whitaker, a UK GP who recently moved to Canada, wrote in the New Statesman that an AI tool he used was 'not to be trusted'. He said it misinterpreted conversations with patients who asked him about his move from the UK - and recorded notes suggesting patients had recently moved to Canada instead. He added: 'I've caught it recording findings of examinations I haven't performed and detailing advice I haven't given. 'The company that makes it advises users to check its output carefully. 'For me, the time spent reading and editing outweighs any productivity gains.' And an article published by Fortune last month outlined a case in which 'a patient in London was mistakenly invited to a diabetic screening after an AI-generated medical record falsely claimed he had diabetes and suspected heart disease'. However, despite this growing use of AI and the recognition of potential problems, the MHRA said a search of its database revealed 'no adverse incident reports related to the use of AI scribes'. The government's 10-Year Health Plan says it intends to 'accelerate the adoption and spread of AI technology, such as AI scribes, by streamlining AI regulation'. A new national procurement platform will be set up next year to support GP practices and NHS trusts to adopt new technology safely. Professor Kamila Hawthorne, chair of the RCGP, said: 'AI has enormous potential for transforming the future of our health and patient care. Fewer than one in three Britons are comfortable with the prospect of using new AI features in the NHS App to diagnose their issues, a poll reveals. Health secretary Wes Streeting announced plans to revamp the app as part of Labour's 10-Year Health Plan so every patient could have a 'doctor in their pocket'. But a new survey found 44 per of the public are 'uncomfortable' with trusting the diagnosis and management of their conditions to artificial intelligence, with this figure rising to 60 per cent among pensioners. Only 31 per cent of the 2,030 respondents to the Savanta poll, for the Liberal Democrats, said they are 'comfortable' with the idea. Helen Morgan, the Liberal Democrat's health spokesperson, praised Labour for tackling bureaucracy but added: 'Making the NHS more efficient is of course welcome but it cannot come at the cost of leaving people behind as they try to grapple with digitised services rather than a real life doctor. 'Ministers need to allay these fears by offering support to those who are not digitally literate and older people to ensure that these sweeping changes benefit everyone.' Speaking at the Plan's launch last month, Mr Streeting said: 'The NHS App will become a doctor in your pocket, bringing our health service into the 21st century.' It will use patients' medical records and artificial intelligence to provide instant answers to users' questions and direct them to the best place for care. Dennis Reed, director of Silver Voices, which campaigns for elderly Britons, said at the time 'Elderly people will be sceptical about whether the plan will be delivered and concerned that greater reliance on the app could exclude them from accessing timely care. 'For some, the doctor in their pocket will be padlocked.' 'However, its use is not without risks and so its implementation in general practice must be closely regulated to guarantee patient safety and the security of their data. 'GPs are always open to introducing new technologies that can improve the experience of patients and help cut the administrative burden, and an increasing number of GP practices are now using AI scribing tools to improve the quality and efficiency of their consultations. 'While these tools can offer real benefits, particularly at a time of significant GP workforce pressures, there are some important concerns - particularly around data security of sensitive patient records, data controllership and the risk of inaccuracies. 'We are aware that AI scribes can produce inaccurate or fabricated details, and that they can also misinterpret the nuance of conversations. 'It is important that clinicians review AI-generated documentation for accuracy before adding it to the patient record.' The MHRA said: 'The MHRA is aware of this potential issue in AI enabled tools generally and this includes AI scribe tools. 'We recommend that GPs and healthcare professionals only use tools which are registered medical devices which have been determined to meet the required standards of performance and safety. 'Recently published MHRA guidance clarifies how these technologies qualify as medical devices and while this is specific to digital mental health, the principles apply across digital health applications. 'While not published by the MHRA, NHS England guidance encourages the use only of registered medical devices when used in a clinical context. 'We strongly encourage that all suspected adverse incidents, including suspected inaccuracies are reported to the MHRA via the yellow card scheme.' The watchdog said the yellow card scheme website had been updated to include 'a standalone page for software and AI as medical device'. Earlier this year, the BMA advised practices to pause use of AI scribes until they had carried out data protection and safety checks and sought assurances that the products meet NHS standards.
